Webinars & Presentations

Senior Director of Global Business Development Sean Menarguez discusses quality and safety in cell therapy development through the early adoption of GMP-compliant processes. MaxCyte’s regulatory framework and collaboration-minded approach can help reduce downstream risks to bring your therapies to patients sooner and with fewer complications.

MaxCyte field application scientist Dan Miller presents on cell therapy equipment and solutions for the Cell & Gene Tech Expo. Watch how our platform enables streamlined, scalable and high-performance transfection across a wide range of cell types.

MaxCyte scientist Ashley Strickland-Dietz presents on transfecting immune cells using electroporation for the 2025 International Conference on Lymphocyte Engineering. MaxCyte’s electroporation platform ensures efficiency, versatility, scalability and safety for a variety of cell types.

Jim Brady, Senior Vice President of Technical Applications and Customer Support at MaxCyte, presents on how electroporation enables the development and manufacturing of life-changing cellular therapies.

Theo Roth, MD PhD, Stanford University, presents an overview of electroporation platform and the advantages of non-viral genome targeting. This approach enables large-scale genetic engineering of diverse primary human immune cells while overcoming the challenges of traditional viral vectors.

Overcome the limitations of conventional transfection with MaxCyte electroporation This webinar is for scientists who are struggling to meet the demands of cell engineering in various applications, including cell therapy, cell-based screening and bioproduction. October 30, 2024 Peter Gee, PhD, Senior Field Applications Scientist at MaxCyte, presents on how traditional delivery methods, such as chemical…

Learn about recent breakthroughs in treating blood disorders including sickle cell disease and immune deficiencies with cutting-edge CRISPR and Cas9 technologies.

Listen to this webinar hosted by Cell and Gene Therapy Insights about the latest advancements in cell therapy, specifically using homology-independent targeted insertion of a therapeutically relevant GD2-CAR transgene into the T cell receptor alpha constant (TRAC) locus using nanoplasmid DNA and CRISPR/Cas9 in primary human T cells.

In this enlightening breakout session from The State of CRISPR and Gene Editing summit hosted by Genetic Engineering and Biotechnology News, James Brady, PhD, presents Translating CRISPR-based Therapies to the Clinic with GMP-compliant, Scalable Electroporation.

Two UCLA scientists present their research on gene editing technologies to treat monogenic blood cell diseases at the 2024 ISCT annual meeting. Most human genetic diseases have heterogeneous mutations across the affected gene in different patients. We are approaching two primary immune deficiencies, X-linked Hyper IgM Syndrome and X-linked Agammaglobulinemia, using Cas9-mediated, site-specific insertion of minigene cDNA cassettes into the 5’ end of their respective genes (CD40L and BTK).